Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP.

J Aerosol Med. 2005 Fall;18(3):294-303.

PMID:
16181004
2.

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. Epub 2004 Jun 21.

3.

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Dumont JA, Low SC, Peters RT, Bitonti AJ.

BioDrugs. 2006;20(3):151-60. Review.

PMID:
16724863
4.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

5.

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. Epub 2006 Aug 12. Review.

PMID:
16997417
6.

Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.

Sockolosky JT, Tiffany MR, Szoka FC.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16095-100. doi: 10.1073/pnas.1208857109. Epub 2012 Sep 18.

7.

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.

Seijsing J, Lindborg M, Höidén-Guthenberg I, Bönisch H, Guneriusson E, Frejd FY, Abrahmsén L, Ekblad C, Löfblom J, Uhlén M, Gräslund T.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17110-5. doi: 10.1073/pnas.1417717111. Epub 2014 Nov 18.

8.

Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.

Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M.

Mol Immunol. 2015 Oct;67(2 Pt B):616-24. doi: 10.1016/j.molimm.2015.06.031. Epub 2015 Aug 5.

PMID:
26254986
9.

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Sockolosky JT, Szoka FC.

Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Review.

10.

Fc-mediated transport of nanoparticles across airway epithelial cell layers.

Vllasaliu D, Alexander C, Garnett M, Eaton M, Stolnik S.

J Control Release. 2012 Mar 28;158(3):479-86. doi: 10.1016/j.jconrel.2011.12.009. Epub 2011 Dec 20.

PMID:
22200577
11.

Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion.

Sangwan S, Agosti JM, Bauer LA, Otulana BA, Morishige RJ, Cipolla DC, Blanchard JD, Smaldone GC.

J Aerosol Med. 2001 Summer;14(2):185-95.

PMID:
11681650
12.

Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.

Low SC, Nunes SL, Bitonti AJ, Dumont JA.

Hum Reprod. 2005 Jul;20(7):1805-13. Epub 2005 Apr 7.

PMID:
15817590
13.

Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.

Vallee S, Rakhe S, Reidy T, Walker S, Lu Q, Sakorafas P, Low S, Bitonti A.

J Interferon Cytokine Res. 2012 Apr;32(4):178-84. doi: 10.1089/jir.2011.0048. Epub 2011 Dec 22.

PMID:
22191463
14.

MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells.

Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, Lencer WI, Blumberg RS.

J Immunol. 2001 Mar 1;166(5):3266-76.

15.

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.

Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, Lencer WI, Pierce GF, Blumberg RS.

Crit Rev Biotechnol. 2015 Jun;35(2):235-54. doi: 10.3109/07388551.2013.834293. Epub 2013 Oct 24. Review.

16.

A comprehensive review of the neonatal Fc receptor and its application in drug delivery.

Martins JP, Kennedy PJ, Santos HA, Barrias C, Sarmento B.

Pharmacol Ther. 2016 May;161:22-39. doi: 10.1016/j.pharmthera.2016.03.007. Epub 2016 Mar 22. Review.

PMID:
27016466
17.

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung.

Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI.

J Exp Med. 2002 Aug 5;196(3):303-10. Erratum in: J Exp Med. 2003 Jun 2;197(11):1601.

18.

Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.

Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V.

J Immunol Methods. 2013 Apr 30;390(1-2):81-91. doi: 10.1016/j.jim.2013.01.011. Epub 2013 Feb 4.

PMID:
23384837
19.

Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.

Zhou L, Wang HY, Tong S, Okamoto CT, Shen WC, Zaro JL.

Biomaterials. 2017 Feb;117:24-31. doi: 10.1016/j.biomaterials.2016.11.051. Epub 2016 Nov 27.

PMID:
27923197
20.

Fc engineering: serum half-life modulation through FcRn binding.

Olafsen T.

Methods Mol Biol. 2012;907:537-56. doi: 10.1007/978-1-61779-974-7_31.

PMID:
22907373

Supplemental Content

Support Center